Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9605150rdf:typepubmed:Citationlld:pubmed
pubmed-article:9605150lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:9605150lifeskim:mentionsumls-concept:C1513095lld:lifeskim
pubmed-article:9605150lifeskim:mentionsumls-concept:C1179435lld:lifeskim
pubmed-article:9605150lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:9605150lifeskim:mentionsumls-concept:C0021747lld:lifeskim
pubmed-article:9605150lifeskim:mentionsumls-concept:C1415900lld:lifeskim
pubmed-article:9605150lifeskim:mentionsumls-concept:C1416479lld:lifeskim
pubmed-article:9605150lifeskim:mentionsumls-concept:C1521761lld:lifeskim
pubmed-article:9605150lifeskim:mentionsumls-concept:C1705248lld:lifeskim
pubmed-article:9605150lifeskim:mentionsumls-concept:C1548799lld:lifeskim
pubmed-article:9605150lifeskim:mentionsumls-concept:C1524073lld:lifeskim
pubmed-article:9605150lifeskim:mentionsumls-concept:C0449432lld:lifeskim
pubmed-article:9605150pubmed:issue11lld:pubmed
pubmed-article:9605150pubmed:dateCreated1998-6-11lld:pubmed
pubmed-article:9605150pubmed:abstractTextIFN-stimulated gene factor 3 (ISGF3) mediates transcriptional activation of IFN-sensitive genes (ISGs). The component subunits of ISGF3, STAT1alphabeta, STAT2, and p48-ISGF3gamma, are tyrosine phosphorylated before their assembly into a complex. Subsequently, the ISGF3 complex is translocated to the nucleus. We have recently established that the responsiveness of human melanoma cell lines to type I IFNs correlates directly with their intracellular levels of ISGF3 components, particularly STAT1. In the present study, we show that pretreating IFN-resistant melanoma cell lines with IFN-gamma (IFN-gamma priming) before stimulation with type I IFN also results in increased levels of ISGF3 components and enhanced DNA-binding activation of ISGF3. In addition, IFN-gamma priming of IFN-resistant melanoma cell lines increased expression of type I IFN-induced ISG products, including ISG54, 2'-5'-oligoadenylate synthase, HLA class I, B7-1, and ICAM-1 Ags. Furthermore, IFN-gamma priming enhanced the antiviral effect of IFN-beta on the IFN-resistant melanoma cell line, MM96. These results support a role for IFN-gamma priming in up-regulating ISGF3, thereby augmenting the responsiveness of IFN-resistant melanoma cell lines to type I IFN and providing a molecular basis and justification for using sequential IFN therapy, as proposed by others, to enhance the use of IFNs in the treatment of melanoma.lld:pubmed
pubmed-article:9605150pubmed:languageenglld:pubmed
pubmed-article:9605150pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9605150pubmed:statusMEDLINElld:pubmed
pubmed-article:9605150pubmed:monthJunlld:pubmed
pubmed-article:9605150pubmed:issn0022-1767lld:pubmed
pubmed-article:9605150pubmed:authorpubmed-author:DevenishR JRJlld:pubmed
pubmed-article:9605150pubmed:authorpubmed-author:RalphS JSJlld:pubmed
pubmed-article:9605150pubmed:authorpubmed-author:Hatzinisiriou...lld:pubmed
pubmed-article:9605150pubmed:authorpubmed-author:WongL HLHlld:pubmed
pubmed-article:9605150pubmed:issnTypePrintlld:pubmed
pubmed-article:9605150pubmed:day1lld:pubmed
pubmed-article:9605150pubmed:volume160lld:pubmed
pubmed-article:9605150pubmed:ownerNLMlld:pubmed
pubmed-article:9605150pubmed:authorsCompleteYlld:pubmed
pubmed-article:9605150pubmed:pagination5475-84lld:pubmed
pubmed-article:9605150pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:meshHeadingpubmed-meshheading:9605150-...lld:pubmed
pubmed-article:9605150pubmed:year1998lld:pubmed
pubmed-article:9605150pubmed:articleTitleIFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs.lld:pubmed
pubmed-article:9605150pubmed:affiliationDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.lld:pubmed
pubmed-article:9605150pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9605150lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9605150lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9605150lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9605150lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9605150lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9605150lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9605150lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9605150lld:pubmed